• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

真实世界证据在加速疫苗部署的监管和公共卫生决策中的作用——会议报告。

The role of real-world evidence for regulatory and public health decision-making for Accelerated Vaccine Deployment- a meeting report.

机构信息

P95 Epidemiology & Pharmacovigilance, Leuven, Belgium.

London School of Hygiene and Tropical Medicine (LSHTM), United Kingdom.

出版信息

Biologicals. 2024 Feb;85:101750. doi: 10.1016/j.biologicals.2024.101750. Epub 2024 Feb 15.

DOI:10.1016/j.biologicals.2024.101750
PMID:38360428
Abstract

The COVID-19 pandemic underscored the need for rapid evidence generation to inform public health decisions beyond the limitations of conventional clinical trials. This report summarises presentations and discussions from a conference on the role of Real-World Evidence (RWE) in expediting vaccine deployment. Attended by regulatory bodies, public health entities, and industry experts, the gathering was a collaborative exchange of experiences and recommendations for leveraging RWE for vaccine deployment. RWE proved instrumental in refining decision-making processes to optimise dosing regimens, enhance guidance on target populations, and steer vaccination strategies against emerging variants. Participants felt that RWE was successfully integrated into lifecycle management, encompassing boosters and safety considerations. However, challenges emerged, prompting a call for improvements in data quality, standardisation, and availability, acknowledging the variability and potential inaccuracies in data across diverse healthcare systems. Regulatory transparency should also be prioritised to foster public trust, and improved collaborations with governments are needed to streamline data collection and navigate data privacy regulations. Moreover, building and sustaining resources, expertise, and infrastructure in LMICs emerged as imperative for RWE-generating capabilities. Continued stakeholder collaboration and securing adequate funding emerged as vital pillars for advancing the use of RWE in shaping responsive and effective public health strategies.

摘要

新冠疫情凸显了在常规临床试验的限制之外快速生成证据以告知公共卫生决策的必要性。本报告总结了一次关于真实世界证据(RWE)在加速疫苗部署方面作用的会议上的演示和讨论。会议邀请了监管机构、公共卫生实体和行业专家参加,是一次经验交流和利用 RWE 进行疫苗部署的建议的合作会议。RWE 在完善决策过程以优化剂量方案、增强针对目标人群的指导以及指导针对新出现变异株的疫苗接种策略方面发挥了重要作用。与会者认为 RWE 已成功地融入了生命周期管理,包括加强针和安全性考虑。然而,出现了一些挑战,因此呼吁提高数据质量、标准化和可用性,承认在不同的医疗保健系统中数据存在变异性和潜在的不准确性。还应优先考虑监管透明度,以增强公众信任,并加强与政府的合作,以简化数据收集并应对数据隐私法规。此外,在 LMIC 中建立和维持资源、专业知识和基础设施对于产生 RWE 的能力至关重要。利益相关者的持续合作和确保充足的资金是推进 RWE 在制定有针对性和有效的公共卫生策略方面的使用的重要支柱。

相似文献

1
The role of real-world evidence for regulatory and public health decision-making for Accelerated Vaccine Deployment- a meeting report.真实世界证据在加速疫苗部署的监管和公共卫生决策中的作用——会议报告。
Biologicals. 2024 Feb;85:101750. doi: 10.1016/j.biologicals.2024.101750. Epub 2024 Feb 15.
2
Use of real-world evidence for oncology clinical decision making in emerging economies.新兴经济体中使用真实世界证据进行肿瘤学临床决策。
Future Oncol. 2021 Aug;17(22):2951-2960. doi: 10.2217/fon-2021-0425. Epub 2021 May 28.
3
Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative.提高透明度以建立对假设检验的真实世界二次数据研究的信任——原因、内容和方法:来自真实世界证据透明度倡议的建议和路线图。
Value Health. 2020 Sep;23(9):1128-1136. doi: 10.1016/j.jval.2020.04.002.
4
Improving transparency to build trust in real-world secondary data studies for hypothesis testing-Why, what, and how: recommendations and a road map from the real-world evidence transparency initiative.提高透明度以增强对用于假设检验的真实世界二次数据研究的信任——为何、是什么以及如何做:来自真实世界证据透明度倡议的建议和路线图
Pharmacoepidemiol Drug Saf. 2020 Nov;29(11):1504-1513. doi: 10.1002/pds.5079. Epub 2020 Sep 13.
5
Use of RWE to Inform Regulatory, Public Health Policy, and Intervention Priorities for the Developing World.利用真实世界证据为发展中国家的监管、公共卫生政策和干预重点提供信息。
Clin Pharmacol Ther. 2022 Jan;111(1):44-51. doi: 10.1002/cpt.2449. Epub 2021 Oct 31.
6
Patient-Community Perspectives on Real-World Evidence: Enhancing Engagement, Understanding, and Trust.患者-社区视角下的真实世界证据:增进参与、理解与信任。
Patient. 2019 Aug;12(4):375-381. doi: 10.1007/s40271-019-00356-z.
7
Use of real-world evidence in cancer drug funding decisions in Canada: a qualitative study of stakeholders' perspectives.加拿大癌症药物资助决策中真实世界证据的应用:对利益相关者观点的定性研究
CMAJ Open. 2020 Nov 24;8(4):E772-E778. doi: 10.9778/cmajo.20200118. Print 2020 Oct-Dec.
8
A Comprehensive Framework for Evaluating the Value Created by Real-World Evidence for Diverse Stakeholders: The Case for Coordinated Registry Networks.用于评估真实世界证据为不同利益相关者创造的价值的综合框架:以协作登记网络为例。
Ther Innov Regul Sci. 2024 Nov;58(6):1042-1052. doi: 10.1007/s43441-024-00680-z. Epub 2024 Jul 25.
9
Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration.开发将真实世界证据纳入癌症药物资助决策框架:加拿大癌症药物价值的真实世界证据(CanREValue)合作。
BMJ Open. 2020 Jan 7;10(1):e032884. doi: 10.1136/bmjopen-2019-032884.
10
Can we use existing guidance to support the development of robust real-world evidence for health technology assessment/payer decision-making?我们能否利用现有指南来支持针对卫生技术评估/支付方决策制定的强有力的真实世界证据的发展?
Int J Technol Assess Health Care. 2022 Nov 2;38(1):e79. doi: 10.1017/S0266462322000605.

引用本文的文献

1
Beyond the Pandemic Era: Recent Advances and Efficacy of SARS-CoV-2 Vaccines Against Emerging Variants of Concern.后疫情时代:SARS-CoV-2疫苗针对新出现的关注变异株的最新进展与效果
Vaccines (Basel). 2025 Apr 17;13(4):424. doi: 10.3390/vaccines13040424.
2
Looking beyond the origin of SARS-CoV-2: Significant strategic aspects during the five-year journey of COVID-19 vaccine development.超越新冠病毒的起源:新冠疫苗研发五年历程中的重要战略层面
Mol Ther Nucleic Acids. 2025 Mar 28;36(2):102527. doi: 10.1016/j.omtn.2025.102527. eCollection 2025 Jun 10.
3
Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Adults with Underlying Medical Conditions: Systematic Literature Review and Pairwise Meta-Analysis Using GRADE.
mRNA-1273和BNT162b2新冠疫苗在有基础疾病的成年人中的比较效果:使用GRADE的系统文献综述和成对荟萃分析
Adv Ther. 2025 May;42(5):2040-2077. doi: 10.1007/s12325-025-03117-7. Epub 2025 Mar 10.
4
Knowledge and Attitudes Regarding Respiratory Syncytial Virus (RSV) Prevention: A Systematic Review.关于呼吸道合胞病毒(RSV)预防的知识与态度:一项系统综述
Vaccines (Basel). 2025 Feb 6;13(2):159. doi: 10.3390/vaccines13020159.
5
Platform Technology in Global Vaccine Regulation: Development, Applications, and Regulatory Strategies with Insights from China.全球疫苗监管中的平台技术:发展、应用及监管策略——来自中国的见解
Vaccines (Basel). 2024 Dec 20;12(12):1436. doi: 10.3390/vaccines12121436.
6
Evaluating the Effectiveness of mRNA-1273.815 Against COVID-19 Hospitalization Among Adults Aged ≥ 18 Years in the United States.评估mRNA-1273.815对美国18岁及以上成年人因COVID-19住院治疗的有效性。
Infect Dis Ther. 2025 Jan;14(1):199-216. doi: 10.1007/s40121-024-01091-1. Epub 2024 Dec 21.
7
Biases in COVID-19 vaccine effectiveness studies using cohort design.使用队列设计的COVID-19疫苗有效性研究中的偏倚。
Front Med (Lausanne). 2024 Oct 30;11:1474045. doi: 10.3389/fmed.2024.1474045. eCollection 2024.
8
[Not Available].[无可用内容]。
MedComm (2020). 2024 Jul 5;5(7):e646. doi: 10.1002/mco2.646. eCollection 2024 Jul.